Objectives: 18F-choline positron emission tomography (PET)/computed tomography (CT) is an integral part in restaging of patients with prostate cancer (PC). The aim of this study was to describe the whole-body physiologic distribution of 18F-choline and to discuss some abnormal sites of uptake not related to PC we observed.
Materials And Methods: Eighty consecutive patients submitted to 18F-choline PET/CT imaging for primary staging or biochemical recurrence (prostate specific antigen rising) after treatment of PC was considered. Whole-body PET/CT was acquired approximately 40 min after 18F-choline injection.
Results: We observed physiological 18F-choline uptake in liver, pancreas, spleen, salivary and lachrymal glands and also, owing to renal excretion, in urinary tract. Other sites of less intense tracer uptake were bone marrow and intestines. We found abnormal and unexpected PET findings in 15 patients (18.7%), not owing to PC localizations. The majority of these findings were owing to inflammation (12 of 15); a case of low grade lymphoma was detected; two patients showed focal brain uptake of 18F-choline and were subsequently submitted to magnetic resonance: in one a meningioma and in the other a low-grade brain tumour were diagnosed.
Conclusion: Accurate knowledge of the biodistribution of 18F-choline is essential for the correct interpretation of PET/CT imaging. CT enables differentiation of physiological bowel activity and 18F-choline excretion in the ureters. In our series, 18F-choline uptake in benign pathological conditions mainly included sites of inflammation; nevertheless, accumulation in tumour deposits not because PC cannot be excluded, particularly in the brain, where correlative imaging with magnetic resonance is of the utmost importance.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/mnm.0b013e328330adc5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[F]fluorocholine PET . [Tc]sestamibi scintigraphy for detection and localization of hyperfunctioning parathyroid glands in patients with primary hyperparathyroidism: outcomes and resource efficiency.
Radiol Oncol
December 2024
Division of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Article Synopsis
- - Minimally invasive parathyroidectomy is the preferred treatment for primary hyperparathyroidism, but it relies on effective preoperative localization methods to identify overactive parathyroid tissue.
- - A study compared two groups of patients—234 who had traditional MIBI scintigraphy and 163 who had FCh-PET/CT—focusing on the efficiency and outcomes of these imaging techniques leading up to surgery.
- - Results showed that FCh-PET/CT significantly reduced imaging time by 83% and surgery time by 41% without using intraoperative hormone monitoring, suggesting it may lead to faster procedures and fewer reoperations for patients.
Testicular Incidentaloma on F-choline PET/CT in a Patient with Prostatic Adenocarcinoma.
Mol Imaging Radionucl Ther
October 2024
Mohammed V Military Training Hospital, Clinic of Nuclear Medicine, Rabat, Morocco.
Prostatic adenocarcinoma is characterized by elevated phosphatidylcholine metabolism. F-choline positron emission tomography/computed tomography (PET/CT) is widely used for patients with biochemical recurrence and a prostate-specific antigen threshold above 2 ng/mL. We report a case of a patient with high-risk prostatic adenocarcinoma undergoing F-choline PET/CT for biochemical recurrence.
View Article and Find Full Text PDFLong-term Results of Hypofractionated Radiotherapy With Intra-prostatic Boosts in Men With Intermediate- and High-risk Prostate Cancer: A Phase II Trial.
Clin Oncol (R Coll Radiol)
December 2024
Department of Radiotherapy, Clatterbridge Cancer Centre, 65 Pembroke Place, Liverpool, UK.
Aims: In the conventionally fractionated phase III FLAME prostate trial, focal boosts improved local control and biochemical disease-free survival (bDFS). We explored the toxicity and effectiveness of a moderately hypofractionated schedule with focal boosts.
Material And Methods: BIOPROP20 is a phase II single-arm non-randomised trial for intermediate- to very high-risk localised prostate cancer patients with bulky tumour volumes.
3,3-Dimethyl-1-Butanol and its Metabolite 3,3-Dimethylbutyrate Ameliorate Collagen-induced Arthritis Independent of Choline Trimethylamine Lyase Activity.
Inflammation
August 2024
Division of Rheumatology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Conflicting data exist in rheumatoid arthritis and the collagen-induced arthritis (CIA) murine model of autoimmune arthritis regarding the role of bacterial carnitine and choline metabolism into the inflammatory product trimethylamine (TMA), which is oxidized in the liver to trimethylamine-N-oxide (TMAO). Using two published inhibitors of bacterial TMA lyase, 3,3-dimethyl-1-butanol (DMB) and fluoromethylcholine (FMC), we tested if TMA/TMAO were relevant to inflammation in the development of CIA. Surprisingly, DMB-treated mice demonstrated > 50% reduction in arthritis severity compared to FMC and vehicle-treated mice, but amelioration of disease was independent of TMA/TMAO production.
View Article and Find Full Text PDFCorrelation of PSA blood levels with standard uptake value maximum (SUV max ) and total metabolic tumor volume (TMTV) in 18F-PSMA-1007 and 18F-choline PET/CT in patients with biochemically recurrent prostate cancer.
Nucl Med Commun
November 2024
Department of Nuclear Medicine, Evaggelismos General Hospital, Athens and .
Objectives: In this prospective study, we investigated the correlation between prostate-specific antigen (PSA) levels in the blood of patients with prostate cancer in biochemical recurrence after radical treatment with the semiquantitative parameters standard uptake value maximum (SUV max ) and the total metabolic tumor volume (TMTV) in the metastatic foci depicted in 18F-prostate-specific membrane antigen (PSMA)-1007 and 18F-choline PET/computed tomography (CT) imaging.
Methods: We prospectively examined 104 patients with biochemical relapse of prostate cancer after primary definitive treatment. All patients underwent one 18F-PSMA-1007 and one 18F-choline PET/CT examination in randomized order within a time frame of 10 days and were followed for at least 6 months (182 ± 10 days).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!